August 25, 2017 06:20 AM EDT
Pharma

Af­ter a long clin­i­cal odyssey, the FDA tapped this PhI­II an­ti-CCR4 as a ‘break­through’ lym­phoma drug

John Carroll

Editor & Founder

A day af­ter Ky­owa Hakko Kirin and Ul­tragenyx filed their ap­pli­ca­tion to sell buro­sum­ab, the Japan­ese phar­ma com­pa­ny is fol­low­ing up with the news that …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

Am­gen names Stan­ford ge­neti­cist and biotech founder to CSO post

FDA vac­cine chief Pe­ter Marks pledges to stay as long as he's wel­come

Cal­tech spin­out de­buts with AI-dri­ven 'mir­ror pep­tide' plat­form

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times